Skip to content

RxSight, Inc. (RXST) – BUY Signal Amid Recovery Regime and Upcoming Q3 Results

2026-10-23 · By Pierre Brunelle · Founder & Research Lead · All notes

RXSTBuyRecovery regimebuy flip

RxSight, Inc. closed at $5.08, up 3.67% on the Thursday session of 2026‑10‑22. The LOPJLB proprietary scanner now flags a BUY directional signal with a perfect Score 5 while the broader market regime has shifted into a RECOVERY phase.

Catalysts & Recent News

Fundamentals and Valuation

RxSight’s balance sheet and income statement paint a picture of a company still in the investment‑heavy growth phase. The trailing twelve‑month (TTM) price‑to‑earnings ratio sits at ‑4.50, reflecting a loss‑generating operation. Enterprise value to EBITDA is similarly negative at ‑4.82, a direct consequence of operating losses that outweigh earnings before interest, taxes, depreciation, and amortization.

Margins remain a mixed bag. The firm enjoys a gross margin of 77.5%, a testament to the high‑margin nature of its proprietary lens technology. However, operating margin is ‑43.2% and net margin ‑36.8%, indicating that SG&A, R&D, and other overhead costs are still consuming a large share of revenue. The free‑cash‑flow yield is ‑12.86%, underscoring that cash generation is currently negative, though the company’s cash burn has narrowed compared with prior years.

Return metrics are equally stark. Return on invested capital (ROIC) stands at ‑10.41%, while return on equity (ROE) and return on assets (ROA) are ‑17.35% and ‑13.31%, respectively. These figures reflect the ongoing transition from a development‑centric business model to a commercial‑scale operation.

The capital structure is leveraged, with a debt‑to‑equity ratio of 4.02 and an interest coverage ratio of ‑3,674.2, indicating that earnings are insufficient to cover interest obligations. Nonetheless, the company’s book‑value multiple is modest at 0.80, suggesting that the market is pricing the firm at less than its net asset value.

Analyst sentiment is cautiously optimistic. The consensus target price is $7.31, implying a potential upside of roughly 44% from the current $5.08 level. The prevailing recommendation is a Hold, reflecting a view that the stock may need additional catalyst confirmation before a consensus upgrade.

Below is a snapshot of the most salient valuation metrics:

MetricValue
P/E (TTM)‑4.50
EV/EBITDA (TTM)‑4.82
Gross Margin77.5 %
Operating Margin‑43.2 %
Net Margin‑36.8 %
Debt‑to‑Equity4.02
Analyst Target Price$7.31

Multi‑Year Financial Trajectory

A review of RxSight’s historical financials from 2020 through 2025 illustrates a steep revenue ascent paired with persistent losses. Revenue grew from $14.68 M in 2020 to a peak of $139.93 M in 2024, before a modest decline to $134.48 M in 2025—a 3.9% year‑over‑year contraction that coincided with a slowdown in lens adoption amid supply‑chain constraints.

Earnings per share (EPS) have been negative since 2021, with the most recent figure at ‑$0.95 for 2025, an improvement over the ‑$1.41 reported in 2023 but still far from profitability. Free cash flow (FCF) has trended less negative, moving from ‑$37.74 M in 2020 to ‑$19.39 M in 2025, indicating incremental progress in cash‑flow management.

Margins have improved dramatically on the gross side, climbing from 11.62% in 2020 to 76.60% in 2025, driven by scaling of the LAL platform and better cost efficiencies in lens manufacturing. Operating margins, while still negative, have narrowed from ‑241.2% in 2020 to ‑35.84% in 2025, reflecting disciplined expense control as the commercial team expands.

Return metrics have remained in the negative territory throughout the period, but the magnitude of the decline has lessened. ROE fell from ‑9.27% in 2020 to ‑14.13% in 2025, while ROA moved from 27.39% (a statistical outlier due to low asset base) to ‑12.49%, underscoring the need for continued earnings improvement.

Overall, the company’s financial narrative is one of rapid top‑line growth offset by a lagging bottom line—a classic profile for a medical‑device firm transitioning from R&D to commercial scale.

LOPJLB Signal Read

The LOPJLB engine currently issues a BUY directional signal for RxSight, set against a RECOVERY market regime that has persisted for four days. The composite PERF score of ‑9.10 reflects recent price weakness, while the FUND quality score of 1.52 points to modest underlying fundamentals. In the value‑growth spectrum, RxSight scores 0.00 on the value side, 29.00 on growth, 4.59 on GARP, and 1.52 on quality, classifying the stock under the Balanced archetype.

Investors can explore the full overlay of technical and quantitative signals on the interactive chart above the article. For a deeper dive into the methodology that drives these scores, visit the LOPJLB methodology page.

Explore more:

The content above is for informational research purposes only and does not constitute investment advice. All readers should conduct their own due diligence before making any trading decisions.

This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.

RXST on today's desk

The note is a snapshot. The stock page and screener carry tonight's re-score, the regime and the backtest behind the call.

OPEN RXST →OPEN THE SCREENER →